GLP-1 receptor agonists — Ozempic, Wegovy, Mounjaro, and Zepbound — have transformed diabetes and weight-loss treatment, but their costs remain punishing without insurance coverage. This guide covers 2026 cash prices, manufacturer savings programs, and what to do when your insurer denies coverage.
Novo Nordisk (Ozempic, Wegovy) and Eli Lilly (Mounjaro, Zepbound) offer savings cards that can drop commercially-insured patients' copay to as low as $25/month. These programs exclude Medicare and Medicaid enrollees.
Most commercial plans cover GLP-1s for Type 2 diabetes (Ozempic, Mounjaro) but deny coverage for weight-loss indications (Wegovy, Zepbound) absent documented comorbidities. Medicare Part D does not cover weight-loss drugs by statute, though diabetes use is generally covered.
Upload your pharmacy EOB or denial letter and Medigami finds coupon stacks, manufacturer assistance programs, and generates appeal letters citing the clinical guidelines that support GLP-1 coverage for your diagnosis.
Educational information only. Not legal, medical, or insurance advice. Statutes, deadlines, and eligibility thresholds vary by plan type and state — consult a licensed attorney, state-certified insurance counselor, or nonprofit patient advocate about your specific situation.
Loading Medigami...
We check any medical bill against standard Medicare rates and flag overcharges, duplicates, and billing mistakes — in about 60 seconds.
Built for fertility patients: we check every line of an IVF bill, flag low-value add-ons, and include a cost estimator that uses your state's rules plus a clinic finder.
Educational tool — not legal, medical, or billing-counsel advice. Treatment and appeal decisions remain with you and your physician / counsel.